ImmuPharma plc (LON:IMM – Get Free Report) traded up 12.5% during trading on Friday . The stock traded as high as GBX 4.50 and last traded at GBX 4.50. Approximately 660,701 shares were traded during mid-day trading, a decline of 75% from the average session volume of 2,689,021 shares. The stock had previously closed at GBX 4.
ImmuPharma Price Performance
The firm’s 50 day moving average price is GBX 4.21 and its 200-day moving average price is GBX 5.38. The firm has a market cap of £28.08 million, a price-to-earnings ratio of -12.16 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. Analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
